Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
CH1243598427
Mon, 14.09.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Bond
Sandoz issues EUR 500 million bond 14.09.2026 / 17:40 CET/CEST
MEDIA RELEASENOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
Bond issuance with principal amount of EUR 500 million and 12 years maturity
Proceeds from bond issuance will be used for general corpo [ … ]
Thu, 09.07.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Regulatory Admission
Sandoz moves up Swiss equity rankings to join premier Swiss Market Index 09.07.2026 / 07:00 CET/CEST
MEDIA RELEASE
Basel, 9 July 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announces that it will be included in the Swiss Market Ind [ … ]
Wed, 17.06.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Expansion
Sandoz steps up in-house biosimilar capabilities, opening state-of-the-art development centre to capture ‘golden decade’ opportunity 17.06.2026 / 07:00 CET/CEST
MEDIA RELEASE
Marking 20 years since launch of world’s first biosimilar, Sandoz opens new biosimilar development centre in L [ … ]
Fri, 15.05.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Regulatory Approval
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes 15.05.2026 / 13:00 CET/CEST
MEDIA RELEASE
Biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart) approve [ … ]
Wed, 15.04.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Agreement
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets 15.04.2026 / 07:00 CET/CEST
MEDIA RELEASE
Strategic partnership with Rwandan government to directly supply critical medicines, including antibiotics [ … ]
Wed, 18.03.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Agreement
Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets 18.03.2026 / 08:30 CET/CEST
MEDIA RELEASE
Agreement for up to five biosimilar assets, with potential for further collaboration; first asset [ … ]
Wed, 11.03.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Bond
Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year 11.03.2026 / 07:00 CET/CEST
MEDIA RELEASENOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
Dual-tranche CHF bond issuance with total principal amount of CHF [ … ]
Wed, 18.02.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Regulatory Approval
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications 18.02.2026 / 07:00 CET/CEST
MEDIA RELEASE
Approved indications now include all retinal indications, in addition to previously-approved indication of nAMD
More than 30 [ … ]
Wed, 14.01.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Regulatory Approval
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes 14.01.2026 / 12:00 CET/CEST
Biosimilar Ondibta® (insulin glargine) approved for treatment of diabetes mellitus across all indicati [ … ]
Mon, 12.01.2026
Sandoz Group AG
Sandoz Group AG
/ Key word(s): Conference
Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity 12.01.2026 / 15:00 CET/CEST
After consistently delivering on commitments in first two years as standalone compan [ … ]
